| MeSH term | MeSH ID | Detail |
|---|---|---|
| Malaria, Falciparum | D016778 | 22 associated lipids |
| Leishmaniasis, Cutaneous | D016773 | 6 associated lipids |
| Pneumocystis Infections | D016720 | 1 associated lipids |
| Vaginosis, Bacterial | D016585 | 10 associated lipids |
| Purpura, Thrombocytopenic, Idiopathic | D016553 | 4 associated lipids |
| Bronchial Hyperreactivity | D016535 | 15 associated lipids |
| Helicobacter Infections | D016481 | 21 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Uveitis, Intermediate | D015867 | 3 associated lipids |
| Erythema Chronicum Migrans | D015787 | 3 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saint-Criq V et al. | Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients. | 2011 | Antimicrob. Agents Chemother. | pmid:21220528 |
| Euba B et al. | Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection. | 2015 | Antimicrob. Agents Chemother. | pmid:25712355 |
| Shigemura K et al. | Azithromycin resistance and its mechanism in Neisseria gonorrhoeae strains in Hyogo, Japan. | 2015 | Antimicrob. Agents Chemother. | pmid:25712352 |
| Peric M et al. | Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. | 2003 | Antimicrob. Agents Chemother. | pmid:12604536 |
| Imamura Y et al. | Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. | 2004 | Antimicrob. Agents Chemother. | pmid:15328111 |
| Soltow SM and Brenner GM | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2007 | Antimicrob. Agents Chemother. | pmid:17060522 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Solomon AW et al. | Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. | 2005 | Antimicrob. Agents Chemother. | pmid:16251338 |
| Bohte R et al. | Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. | 1995 | Antimicrob. Agents Chemother. | pmid:8593024 |
| Vaara M | Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. | 1993 | Antimicrob. Agents Chemother. | pmid:8383945 |
| Brown ST et al. | Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. | 1993 | Antimicrob. Agents Chemother. | pmid:8384809 |
| Ohrt C et al. | Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. | 2002 | Antimicrob. Agents Chemother. | pmid:12121927 |
| Gladue RP and Snider ME | Intracellular accumulation of azithromycin by cultured human fibroblasts. | 1990 | Antimicrob. Agents Chemother. | pmid:2168141 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Watt G et al. | Azithromycin activities against Orientia tsutsugamushi strains isolated in cases of scrub typhus in Northern Thailand. | 1999 | Antimicrob. Agents Chemother. | pmid:10543774 |
| Grinwis ME et al. | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. | 2010 | Antimicrob. Agents Chemother. | pmid:20404127 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Schmalstieg AM et al. | The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22751536 |
| Bulman ZP et al. | Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. | 2017 | Antimicrob. Agents Chemother. | pmid:28096154 |
| Capobianco JO and Goldman RC | Erythromycin and azithromycin transport into Haemophilus influenzae ATCC 19418 under conditions of depressed proton motive force (delta mu H). | 1990 | Antimicrob. Agents Chemother. | pmid:2178338 |
| Gorby GL and McGee ZA | Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells. | 1990 | Antimicrob. Agents Chemother. | pmid:1982402 |
| Bonnet M and Van der Auwera P | Preincubation of Haemophilus influenzae with subinhibitory concentrations of macrolides: influence on human neutrophil chemiluminescence. | 1993 | Antimicrob. Agents Chemother. | pmid:8390808 |
| Gordillo ME et al. | In vitro activity of azithromycin against bacterial enteric pathogens. | 1993 | Antimicrob. Agents Chemother. | pmid:8390813 |
| Kobuchi S et al. | Transport of Azithromycin into Extravascular Space in Rats. | 2016 | Antimicrob. Agents Chemother. | pmid:27600045 |
| Goldman RC and Capobianco JO | Role of an energy-dependent efflux pump in plasmid pNE24-mediated resistance to 14- and 15-membered macrolides in Staphylococcus epidermidis. | 1990 | Antimicrob. Agents Chemother. | pmid:1963291 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Mallegol J et al. | Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. | 2014 | Antimicrob. Agents Chemother. | pmid:24277019 |
| Blais J et al. | Inhibition of Toxoplasma gondii protein synthesis by azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8215287 |
| Bermudez LE et al. | Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11120969 |
| Edelstein PH and Edelstein MA | In vitro activity of azithromycin against clinical isolates of Legionella species. | 1991 | Antimicrob. Agents Chemother. | pmid:1849708 |
| Fuentes F et al. | Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. | 1998 | Antimicrob. Agents Chemother. | pmid:9527796 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Itaqui SR et al. | In Vitro Synergism between Azithromycin or Terbinafine and Topical Antimicrobial Agents against Pythium insidiosum. | 2016 | Antimicrob. Agents Chemother. | pmid:27216049 |
| Matic V et al. | Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:15504828 |
| Kosowska K et al. | Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. | 2004 | Antimicrob. Agents Chemother. | pmid:15504829 |
| Ouyang-Latimer J et al. | In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. | 2011 | Antimicrob. Agents Chemother. | pmid:21115800 |
| Vazifeh D et al. | Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9333032 |
| Nakajima T et al. | Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy. | 2016 | Antimicrob. Agents Chemother. | pmid:26729495 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Carvalho-Assef AP et al. | Detection of NDM-1-, CTX-M-15-, and qnrB4-producing Enterobacter hormaechei isolates in Brazil. | 2014 | Antimicrob. Agents Chemother. | pmid:24449772 |
| Agacfidan A et al. | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. | 1993 | Antimicrob. Agents Chemother. | pmid:8239579 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Tomazic J et al. | In vivo administration of azithromycin affects lymphocyte activity in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:8239585 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Cantin L and Chamberland S | In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8239619 |
| Roblin PM and Hammerschlag MR | In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. | 1998 | Antimicrob. Agents Chemother. | pmid:9624507 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Pérez-MartÃnez I and Haas D | Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. | 2011 | Antimicrob. Agents Chemother. | pmid:21537014 |
| Odenholt I et al. | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. | 1997 | Antimicrob. Agents Chemother. | pmid:9371360 |
| Kosowska-Shick K et al. | Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. | 2006 | Antimicrob. Agents Chemother. | pmid:17043120 |